Hemodynamic effect of methylepoxyproscillaridin (P35) in patients with congestive myocardiopathy.
The hemodynamic effect of methylepoxyproscillaridin (3'-methyl-4'-5'-epoxy-proscillaridin) (P35) was studied according to the Swan Ganz thermodilution method in 6 patients with latent cardiac insufficiency. Both at rest and under ergometer exercise, the stroke volume and the systolic blood pressures increased under P35. Moreover, under physical exercise the heart rate decreased significantly, while cardiac output increased. The hemodynamic effect of P35 can therefore be regarded as typical of cardiac glycosides.
Bonelli
J
J
1st Medical University Clinic Vienna.
Magometschnig
D
D
Gazo
F
F
D000368:Aged; D001794:Blood Pressure / Q000187:drug effects; D002018:Bufanolides / Q000494:pharmacology*; D002301:Cardiac Glycosides / Q000494:pharmacology*; D006333:Heart Failure / Q000503:physiopathology*; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D008875:Middle Aged; D011442:Proscillaridin / Q000031:analogs & derivatives / Q000494:pharmacology*; D013318:Stroke Volume / Q000187:drug effects
D002018:Bufanolides; D002301:Cardiac Glycosides; C056946:methylepoxyproscillaridin; D011442:Proscillaridin